Targeting B cell responses in universal influenza vaccine design
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Since its first administration in the 1940s, the influenza vaccine has provided tremendous relief against influenza infections. However, time has revealed the vaccine’s ultimate limit and the call for its reinvention has now come, just as we are beginning to appreciate the antibody immune responses vital in preventing infections. New strategies to design the influenza vaccine rely on selectively inducing broadly neutralizing antibodies that are specific for highly conserved viral epitopes. Such approaches take us away from the limited range of protection provided by current seasonal influenza vaccines and towards a future with a pan-influenza vaccine capable of providing universal strain coverage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibody neutralization and escape by HIV-1
Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., et al. (2003) · Nature · doi:10.1038/nature01470 · Cited by 2,421
Antibody Recognition of a Highly Conserved Influenza Virus Epitope
Ekiert, D. C., Bhabha, G., Elsliger, M.-A., Friesen, R. H. E., Jongeneelen, M., Throsby, M., Goudsmit, J., & Wilson, I. A. (2009) · Science · doi:10.1126/science.1171491 · Cited by 1,326
Corti, D., Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G., Pinna, D., Minola, A., Vanzetta, F., et al. (2011) · Science · doi:10.1126/science.1205669 · Cited by 1,203
Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution
Varghese, J. N., Laver, W. G., & Colman, P. M. (1983) · Nature · doi:10.1038/303035a0 · Cited by 891
Skehel, J. J., Bayley, P. M., Brown, E. B., Martin, S. R., Waterfield, M. D., White, J. M., Wilson, I. A., & Wiley, D. C. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.4.968 · Cited by 726
Cited by
Antibodies in HIV-1 Vaccine Development and Therapy
Klein, F., Mouquet, H., Dosenovic, P., Scheid, J. F., Scharf, L., & Nussenzweig, M. C. (2013) · Science · doi:10.1126/science.1241144 · Cited by 457
Immune history profoundly affects broadly protective B cell responses to influenza
Andrews, S. F., Huang, Y., Kaur, K., Popova, L. I., Ho, I. Y., Pauli, N. T., Dunand, C. J. H., Taylor, W. M., Lim, S., Huang, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad0522 · Cited by 411
Self-citationLau, D., Lan, L. Y.-L., Andrews, S. F., Henry, C., Rojas, K. T., Neu, K. E., Huang, M., Huang, Y., DeKosky, B., Palm, A.-K. E., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aai8153 · Cited by 269
Self-citationHenry Dunand, C. J., Leon, P. E., Huang, M., Choi, A., Chromikova, V., Ho, I. Y., Tan, G. S., Cruz, J., Hirsh, A., Zheng, N.-Y., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.05.014 · Cited by 268
Self-citationKhurana, S., Frasca, D., Blomberg, B., & Golding, H. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002920 · Cited by 85
“Recently, rare antibodies with broad neutralizing cross-reactivity that target the HA2 stem were reported, but they are not easily elicited by traditional vaccination [12].”
BackgroundImpact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection
Merani, S., Pawelec, G., Kuchel, G. A., & McElhaney, J. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00784 · Cited by 74
“It is believed that IgA and IgM specific for viral hemagglutinin (HA) protect against the establishment of initial infection though neutralization of the virus, while IgG antibodies against nucleoprotein (NP) neutralize the virus if infection becomes established (52, 53).”
Background
Metadata
- Authors
- Kaur, K., Sullivan, M., & Wilson, P. C.
- Venue
- Trends in Immunology
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 32
- Issue
- 11
- Pages
- 524-531
- ISSN
- 1471-4906 (ISSN-L)
- OpenAlex
- W2137319366
- Cited by
- 53
- References
- 5
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.